Dynavax Technologies Corp.
NASDAQ:DVAX
| Market Cap (Intraday) | 1.42B |
| Current PE | 82.79 |
| Forward PE | 58 |
| 2yr Forward PE | 29.78 |
| 10-Day MA | $11.13 |
| 50-Day MA | $11.09 |
| 200-Day MA | $11.95 |
Dynavax Technologies Corp. Stock, NASDAQ:DVAX
2100 Powell Street, Suite 900, Emeryville, California 94608
United States of America
Phone: +1.510.848.5100
Number of Employees: 408
Description
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.